Pirfenidone: A Novel Anti-fibrotic Agent and Progressive Chronic Allograft Rejection

Author： Dosanjh A.   Ikonen T.   Wan B.   Morris R.E.  

Publisher： Academic Press

ISSN： 1094-5539

Source： Pulmonary Pharmacology & Therapeutics, Vol.15, Iss.5, 2002-10, pp. : 433-437

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pirfenidone: an anti-fibrotic therapy for progressive kidney disease

By Cho Monique E   Kopp Jeffrey B  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 2, 2010-02 ,pp. : 275-283

Informa Healthcare

Access to resources Recommend Favorite

A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor- at the translational level

By Nakazato H.   Oku H.   Yamane S.   Tsuruta Y.   Suzuki R.  

European Journal of Pharmacology, Vol. 446, Iss. 1, 2002-06 ,pp. : 177-185

Elsevier

Access to resources Recommend Favorite

CCN2: a novel, specific and valid target for anti-fibrotic drug intervention

By Leask Andrew  

Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 9, 2013-09 ,pp. : 1067-1071

Informa Healthcare

Access to resources Recommend Favorite

The effect of HMG-CoA reductase inhibitors on chronic allograft rejection

By Jones T.  

Expert Opinion on Emerging Drugs, Vol. 6, Iss. 1, 2001-04 ,pp. : 95-109

Informa Healthcare

Access to resources Recommend Favorite

Anti-fibrotic effects of tetrandrine on bile-duct ligated rats

By Hsu Yi-Chao   Chiu Yung-Tsung   Lee Chang-Yin   Wu Ching-Fen   Huang Yi-Tsau  

Canadian Journal of Physiology and Pharmacology, Vol. 84, Iss. 10, 2006-10 ,pp. : 967-976

NRC Research Press

Access to resources Recommend Favorite